High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid [1]

AIDS

Volumn 17, Issue 7, 2003, Pages 1105-1107

  Vergne, Laurence ^a   Paraskevis, Dimitris ^b   Vandamme, Anne Mieke ^b   Delaporte, Eric ^a   Peeters, Martine ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; CONTROLLED STUDY; CRFO2 AG STRAIN; DIAGNOSTIC TEST; DRUG SENSITIVITY; EPIDEMIC; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; IN VITRO STUDY; LETTER; MAXIMUM LIKELIHOOD METHOD; MOLECULAR DYNAMICS; NOMENCLATURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; SPAIN; TREATMENT FAILURE; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

EMIGRATION AND IMMIGRATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; SPAIN;

EID: 0038216711     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00028     Document Type: Letter

References (9)

1. Peeters M, Sharp PM. Genetic diversity of HIV-1: the moving target. AIDS 2000; 14 (Suppl. 3):S129-S140.
2. Robertson D, Anderson J, Bradac J, Carr JK, Foley B, Funkhouser RK, et al. HIV-1 nomenclature proposal. Science 2000; 288: 55-56.
3. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type I strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925.
4. Holguin A, Alvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002; 16:1163-1170.
5. Frater A, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15:1493-1502.
6. Laurent C, Diakhate N, Gueye NFN, Touré MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
7. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184:983-991.
8. Lorenzi P, Opravil M, Hirschel B, Chave J-P, Furrer H-J, Sax H, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-F21.
9. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.